Company Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.
The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.
In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products.
Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism.
It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology.
The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
| Country | United States |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 50,000 |
| CEO | Richard A. Gonzalez |
Contact Details
Address: 1 North Waukegan Road North Chicago, Illinois 60064 United States | |
| Phone | (847) 932-7900 |
| Website | abbvie.com |
Stock Details
| Ticker Symbol | ABBV |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001551152 |
| CUSIP Number | 00287Y109 |
| ISIN Number | US00287Y1091 |
| Employer ID | 32-0375147 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard A. Gonzalez | Chairman and Chief Executive Officer |
| Robert A. Michael | President and Chief Operating Officer |
| Scott T. Reents | Executive Vice President and Chief Financial Officer |
| Dr. Azita Saleki-Gerhardt Ph.D. | Executive Vice President and Chief Operating Officer |
| Jeffrey Ryan Stewart | Executive Vice President and Chief Commercial Officer |
| Dr. Thomas J. Hudson M.D. | Senior Vice President and Chief Scientific Officer of Global Research |
| Elizabeth Shea | Senior Vice President of Investor Relations |
| Perry C. Siatis | Executive Vice President, General Counsel and Secretary |
| Sanjay Narayan | Senior Vice President, Chief Ethics, Compliance Officer and Allergan Aesthetic Legal |
| Timothy J. Richmond | Executive Vice President and Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 3, 2024 | 8-K | Current Report |
| Apr 2, 2024 | PX14A6G | Notice of exempt solicitation submitted by non-management |
| Mar 26, 2024 | PX14A6G | Notice of exempt solicitation submitted by non-management |
| Mar 21, 2024 | 144/A | Filing |
| Mar 20, 2024 | 144 | Filing |
| Mar 18, 2024 | 144 | Filing |
| Mar 18, 2024 | ARS | Filing |
| Mar 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 18, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 4, 2024 | PRE 14A | Other preliminary proxy statements |